血清幽门螺杆菌抗体联合胃蛋白酶原检测在胃癌和癌前病变筛查中的作用

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the role of serum Helicobacter pylori (Hp) antibody combined with pepsinogen(PG) detection in the screening of gastric cancer and precancerous lesions. Methods A total of 440 cases of patients with gastric diseases in our hospital From June 2019 to January 2020 were selected as gastric disease group, and 112 cases of healthy people in our hospital were selected as control group. The Hp infections, serum PGⅠ, PGⅡlevels and PGR of the two groups were statistically analyzed. Results Comparison of Hp positive rates and HP negative rates between gastric disease groups (gastric cancer group, gastric ulcer group, atrophic gastritis group, superficial gastritis group) and healthy control group showed no statistically significant differences (P＞0.05). The serum PGⅠlevel of patients in the gastric ulcer group was higher than that of healthy control group (P＜0.05). The serum PGⅠlevel of gastric cancer group and atrophic gastritis group was lower than that of the healthy control group (P＜0.05). The serum PGⅡlevel of gastric cancer group, gastric ulcer group and atrophic gastritis group was higher than that of healthy control group, while the PGR level was lower than that of healthy control group (P＜0.05). There were no significant differences in serum PGⅠ, PGⅡlevels and PGR between the superficial gastritis group and the healthy control group (P＞0.05).There were no statistically significant differences in serum PGⅠ, PGⅡlevels and PGR between Hp positive and Hp negative subjects in gastric cancer group, gastric ulcer group, atrophic gastritis group, superficial gastritis group and healthy control group (P＞0.05). Conclusion In the screening of gastric cancer and precancerous lesions, the detection of Hp antibody and PG has positive clinical diagnostic value and is worthy of promotion.

Key words： Gastric cancer Precancerous lesions Serum Helicobacter pylori antibody Pepsinogen Screening

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yang-yang
	LIN Yu-feng
	CHEN Dong-ling

Cite this article:

LI Yang-yang,LIN Yu-feng,CHEN Dong-ling. Role of Helicobacter pylori serum antibody combined with pepsinogen detection in screening of gastric cancer and precancerous lesions[J]. 中国当代医药, 2020, 27(25): 187-189转193.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I25/187

[1]	李俊，姚保栋，李为希，等.血清幽门螺杆菌抗体、胃蛋白酶原、胃泌素-17 检测对5552 名社区胃癌高危人群的筛查研究[J].中国肿瘤，2019，28（8）：629-635.
[2]	孔凡立，李铮.血清胃蛋白酶原检测对幽门螺杆菌感染相关高危胃癌患者的诊断效果研究[J].中华医院感染学杂志，2019，29（16）：2468-2472.
[3]	王霄腾，吕宾，冀子中.血清幽门螺杆菌抗体联合胃蛋白酶原检测与OLGA/OLGIM 胃炎评价标准在胃癌前病变风险评估中的相关性研究[J].胃肠病学，2019，24（2）：71-75.
[4]	颜海帆，夏晨梅，陈玲玲，等.血清胃蛋白酶原、幽门螺杆菌抗体联合检测对胃癌及癌前病变的早期预测价值[J].中国医师杂志，2017，19（5）：767-769.
[5]	刘刚，赵民学，王德盛.血清胃蛋白酶原、胃泌素17 和幽门螺杆菌抗体检测在胃癌筛查中的应用[J].吉林大学学报（医学版），2017，43（6）：1182-1185.
[6]	王霄腾，蔡利军，吕宾.血清幽门螺杆菌抗体联合胃蛋白酶原检测在胃癌和癌前病变筛查中的应用[J].中华消化杂志，2016，36（9）：582-587.
[7]	刘林，路荣，陈莹，等.胃镜联合血清胃蛋白酶原诊断高危Hp 相关性胃癌的价值研究[J].海南医学院学报，2018，24（2）：185-187.
[8]	金鑫，李树锦，陈贞，等.胃功能三项联合Hp 抗体对胃癌及癌前病变的鉴别诊断价值[J].现代生物医学进展，2018，18（12）：2388-2391.
[9]	党旖旎，许年珍，严谨，等.江苏南部地区早期胃癌及癌前病变筛查结果及分析[J].中华健康管理学杂志，2018，12（1）：26-31.
[10]	吴琼，骆钻芳，谢飚，等.血清Hp IgG、PGⅠ与PGR 水平对胃癌临床筛查的价值[J].热带医学杂志，2017，17（6）：736-739.
[11]	许园园，赵健晢.血清胃蛋白酶原、幽门螺杆菌IgG 抗体在胃癌及癌前病变筛查中的临床研究[J].中国初级卫生保健，2018，32（7）：93-95.
[12]	叶火林.血清胃蛋白酶原与幽门螺杆菌免疫球蛋白G 抗体检测在胃癌及癌前病变筛查中的应用观察[J].中国医学工程，2016，24（9）：19-21.
[13]	李梦颖，马晨，焦晨阳，等.血清胃蛋白酶原和胃泌素-17在胃癌和癌前病变筛查中的价值[J].胃肠病学，2017，22（9）：539-543.
[14]	熊莉娜，马静.胃粘膜血清活检技术在萎缩性胃炎与胃癌筛查中的价值研究[J].现代仪器与医疗，2017，23（5）：81-82，90.
[15]	王萍，史彬，温艳东，等.胃癌前病变病证结合风险预测模型的构建研究[J].中国中西医结合杂志，2018，38（7）：773-778.